Methods for treating cancer with a recombinant MVA expressing HER-2
View Patent ↗The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus.
1. A method for treating a human cancer patient comprising:
(a) administering to the patient a recombinant MVA expressing a polypeptide comprising a HER-2 antigen; and
(b) administering to the patient a tumoricidal dose of a taxane,
wherein administration of the MVA and the taxane in combination is superior to either treatment alone to inhibit tumor growth.
2. The method of claim 1 , wherein the MVA is MVA-BN.
3. The method of claim 1 , wherein the HER-2 antigen comprises SEQ ID NO:2.
4. The method of claim 1 , wherein the recombinant MVA is administered prior to the tumoricidal dose of the taxane.
5. The method of claim 1 , wherein the recombinant MVA is administered at the same time as the tumoricidal dose of the taxane.
6. The method of claim 1 , wherein the recombinant MVA is administered after the tumoricidal dose of the taxane.
7. The method of claim 4 , wherein the taxane is docetaxel.
8. The method of claim 4 , wherein the taxane is paclitaxel.
9. The method of claim 6 , wherein the taxane is docetaxel.
10. The method of claim 6 , wherein the taxane is paclitaxel.
11. The method of claim 7 , wherein the taxane is docetaxel at a dose of 75-100 mg/m 2 .
12. The method of claim 8 , wherein the taxane is paclitaxel at a dose of 135-175 mg/m 2 .
13. The method of claim 9 , wherein the taxane is docetaxel at a dose of 75-100 mg/m 2 .
14. The method of claim 10 , wherein the taxane is paclitaxel at a dose of 135-175 mg/m 2 .
15. The method of claim 4 , wherein the recombinant MVA is administered 1-26 weeks prior to the tumoricidal dose of the taxane.
16. The method of claim 4 , wherein the recombinant MVA is administered 1-3 weeks prior to the tumoricidal dose of the taxane.
17. The method of claim 6 , wherein the recombinant MVA is administered 2-60 days after the tumoricidal dose of the taxane.
18. The method of claim 6 , wherein the recombinant MVA is administered 2-7 days after the tumoricidal dose of the taxane.
19. A kit for treating a cancer patient comprising:
(a) a recombinant MVA expressing a polypeptide comprising a HER-2 antigen; and
(b) instructions to administer the recombinant MVA prior to treatment with a tumoricidal dose of a taxane,
wherein administration of the MVA and the taxane in combination is superior to either treatment alone to inhibit tumor growth.
20. A kit for treating a cancer patient comprising:
(a) a recombinant MVA expressing a polypeptide comprising a HER-2 antigen; and
(b) instructions to administer the recombinant MVA at the same time as treatment with a tumoricidal dose of a taxane,
wherein administration of the MVA and the taxane in combination is superior to either treatment alone to inhibit tumor growth.
21. A kit for treating a cancer patient comprising:
(a) a recombinant MVA expressing a polypeptide comprising a HER-2 antigen; and
(b) instructions to administer the recombinant MVA after treatment with a tumoricidal dose of a taxane,
wherein administration of the MVA and the taxane in combination is superior to either treatment alone to inhibit tumor growth.
22. The kit of claim 19 , wherein the HER-2 antigen comprises SEQ ID NO:2.
23. The kit of claim 20 , wherein the HER-2 antigen comprises SEQ ID NO:2.
24. The kit of claim 21 , wherein the HER-2 antigen comprises SEQ ID NO:2.
25. A recombinant vaccinia virus expressing a polypeptide comprising a HER-2 antigen,
wherein the HER-2 antigen comprises SEQ ID NO:2, and
wherein administration of the MVA and a tumoricidal dose of a taxane in combination is superior to either treatment alone to inhibit tumor growth.